Suppr超能文献

使用高效液相色谱法作为新生儿脐血血红蛋白病筛查工具的验证研究。

The Use of HPLC as a Tool for Neonatal Cord Blood Screening of haemoglobinopathy: A Validation Study.

作者信息

Al-Madhani A, Pathare A, Al Zadjali S, Al Rawahi M, Al-Nabhani I, Alkindi S

机构信息

Department of Medicine, Sohar Hospital, Sohar, Oman.

Department of Haematology, Sultan Qaboos University Hospital, Oman.

出版信息

Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019005. doi: 10.4084/MJHID.2019.005. eCollection 2019.

Abstract

BACKGROUND

Newborn cord blood screening identifies infants with underlying haemoglobinopathies before they develop the characteristic symptoms or sequelae.

AIMS

This study was performed to validate the interpretation high-performance chromatography (HPLC) along with complete blood count (CBC) results as a tool for universal neonatal screening of hemoglobin disorders in Oman.

METHODS

HPLC and CBC data on subjects who participated in the National Neonatal screening program at birth were obtained from archival records. The results recorded at birth were compared with a second study performed on the same subjects, after approval from the local medical research and ethics committee.

RESULTS

Only 290 subjects from amongst the original cohort of 3740 newborns could be recalled between April 2010 to March 2011, to repeat HPLC and CBC, as well as perform confirmatory DNA studies, wherever necessary. All these subjects had been documented to show an initial abnormal result. 31 cases who had no HbA at birth on HPLC were confirmed as either homozygous β-thalassaemia major (n=5 subjects) or homozygous sickle cell anemia (n=26 subjects) by appropriate DNA analysis. Additionally, amongst 151 subjects, 72 subjects were studied in the initial study by Hb Bart's quantitation using the alpha thalassaemia short program at birth. In this cohort, 42 subjects with Hb Bart's >1% at birth could be confirmed as having either deletional or non-deletional thalassaemia by GAP PCR studies. No case of HbH was detected in this cohort. Further, carrier status for structural hemoglobin variants (HbS, HbC, HbD, HbE) (n=67) and beta thalassaemia allele with low HbA at birth (n=29 out of 41) were confirmed by relevant molecular studies.

CONCLUSIONS

The study validated the earlier observation by 100% concordance with the results of CBC and HPLC. Presence of Hb Bart's at birth does not always mean the presence of alpha thalassemia, as subjects with Hb Bart's below 1% by quantitation, were shown to be normal by molecular studies.

摘要

背景

新生儿脐血筛查可在患有潜在血红蛋白病的婴儿出现特征性症状或后遗症之前将其识别出来。

目的

本研究旨在验证高效液相色谱法(HPLC)结合全血细胞计数(CBC)结果作为阿曼新生儿血红蛋白病通用筛查工具的解读。

方法

从档案记录中获取参与国家新生儿出生时筛查项目的受试者的HPLC和CBC数据。在获得当地医学研究与伦理委员会批准后,将出生时记录的结果与对同一受试者进行的第二项研究结果进行比较。

结果

在2010年4月至2011年3月期间,最初的3740名新生儿队列中只有290名受试者被召回,以便重复进行HPLC和CBC检测,并在必要时进行DNA确证研究。所有这些受试者最初的检测结果均记录为异常。通过适当的DNA分析,出生时HPLC检测无HbA的31例病例被确认为纯合子重型β地中海贫血(n = 5例)或纯合子镰状细胞贫血(n = 26例)。此外,在151名受试者中,有72名受试者在最初的研究中于出生时使用α地中海贫血短程序进行了Hb Bart定量检测。在这个队列中,出生时Hb Bart>1%的42名受试者通过缺口聚合酶链反应(GAP PCR)研究可被确认为患有缺失型或非缺失型地中海贫血。该队列中未检测到HbH病例。此外,通过相关分子研究证实了结构血红蛋白变异体(HbS、HbC、HbD、HbE)的携带者状态(n = 67)以及出生时HbA较低的β地中海贫血等位基因(41例中的29例)。

结论

本研究通过与CBC和HPLC结果100%一致验证了早期观察结果。出生时存在Hb Bart并不总是意味着存在α地中海贫血,因为定量检测Hb Bart低于1%的受试者经分子研究显示为正常。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9970/6328035/b7003011fbb3/mjhid-11-1-e2019005f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验